Skip to main content
Clinical Trials/EUCTR2005-000107-33-CZ
EUCTR2005-000107-33-CZ
Active, not recruiting
Phase 1

A 12-week multicentre, randomised, double-blind, parallel group, Phase IIpilot study to evaluate the efficacy and safety of cizolirtine citrate 200 mgbid (400 mg/d), cizolirtine citrate 300 mg bid (600 mg/d) and cizolirtinecitrate 400 mg bid (800 mg/d) versus placebo in the treatment of patientswith Stress Urinary Incontinence (SUI)

aboratorios Dr. Esteve, S.A.0 sites180 target enrollmentOctober 14, 2005

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
aboratorios Dr. Esteve, S.A.
Enrollment
180
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 14, 2005
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Sponsor
aboratorios Dr. Esteve, S.A.

Eligibility Criteria

Inclusion Criteria

  • 1\. Females 18\-75 years of age.
  • 2\. Signed informed consent form.
  • 3\. Clinical diagnosis of stress urinary incontinence for at least 3 months confirmed by
  • medical history and documented in the subject’s file.
  • 4\. Presence of:
  • \-more or equal to 4 incontinence episodes per week. An episode is defined as an easily
  • noticeable leakage of urine that wets a pad or clothing and occurs in association
  • with a physical stress such as coughing, sneezing, or exercise.
  • \- Urinary diurnal frequency less or equal to 8 per day
  • \- Urinary nocturnal frequency IN AVERAGE AT MOST 2 per night

Exclusion Criteria

  • 1\. Evidence of mixed incontinence or urge incontinence, or incontinence due to surgical
  • treatment, according to investigator’s opinion
  • 2\. Evidence of exclusively nocturnal enuresis
  • 3\. Polyuria known from medical history and confirmed during run\-in
  • 4\. Concomitant treatment with drugs introduced within 3 months or with \<3 months of
  • stable dosing and that can be supposed to have effects on the lower urinary tract such
  • as antidepressants, neuroleptics, and calcium blocking agents.
  • 5\. Lower tract urological pathology in the investigator’s opinion potentially responsible for incontinence known from medical history for the last 3 months
  • 6\. Urinary tract infection defined in terms of clinical signs and symptoms, with or without microbiological confirmation, within 2 weeks prior to placebo run\-in (i.e. Visit 2\)
  • 7\. Mechanical obstructive uropathy known from medical history

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A 12-week multicentre, randomised, double-blind, parallel group, Phase IIpilot study to evaluate the efficacy and safety of cizolirtine citrate 200 mgbid (400 mg/d), cizolirtine citrate 300 mg bid (600 mg/d) and cizolirtinecitrate 400 mg bid (800 mg/d) versus placebo in the treatment of patientswith Stress Urinary Incontinence (SUI)Stress Urinary Incontinence
EUCTR2005-000107-33-ESaboratorios Dr. Esteve, S.A.180
Active, not recruiting
Not Applicable
A 12-week multicentre, randomised, double-blind, parallel group, Phase IIpilot study to evaluate the efficacy and safety of cizolirtine citrate 200 mgbid (400 mg/d), cizolirtine citrate 300 mg bid (600 mg/d) and cizolirtinecitrate 400 mg bid (800 mg/d) versus placebo in the treatment of patientswith Stress Urinary Incontinence (SUI)Stress Urinary Incontinence
EUCTR2005-000107-33-SEaboratorios Dr. Esteve, S.A.180
Active, not recruiting
Not Applicable
A 12-week multicentre, randomised, double-blind, parallel group, Phase IIpilot study to evaluate the efficacy and safety of cizolirtine citrate 200 mgbid (400 mg/d), cizolirtine citrate 300 mg bid (600 mg/d) and cizolirtinecitrate 400 mg bid (800 mg/d) versus placebo in the treatment of patientswith Stress Urinary Incontinence (SUI)Stress Urinary Incontinence
EUCTR2005-000107-33-EEaboratorios Dr. Esteve, S.A.180
Active, not recruiting
Not Applicable
A 12 week multi-centre, randomized, double-blind, placebo controlled evaluation of the most efficacious and tolerable dose of escitalopram in the treatment of elderly patients. - Double-blind placebo controlled study of escitalopram in the treatment of depression in the elderlyDepression in the elderly
EUCTR2005-003821-25-DKPsychiatric Hospital189
Active, not recruiting
Phase 3
A clinical trial, involving several sites in several countries, with a duration of 12 weeks, where patients, medical doctors and the sponsor do not know the treatment taken by the patient (between one study treatment and another one) with the scope of evaluating the safety of study treatment in comparison with another similar one in subjects with asthma.AsthmaRespiratory
ISRCTN17142179Chiesi (Italy)513